PharmaBoardroom

Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in…

María Jesús Lamas, director and César Hernández García, head of medicines for human use at the Spanish Agency of Medicine and Health Products…

Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan…

Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the…

Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the…

Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting…

Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir…

In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into…

How Malaysia is setting itself up to provide biosimilars across the Islamic world as well as Asia. Inno Bio Ventures, a Malaysian…

Tan Sri Rahman Mamat, chairman of Inno Bio Ventures, provides his vision for biosimilars’ potential in Malaysia, and the progress the company has…

Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars…

Radwa Terbeche, general manager of Amgen in Algeria discusses the potential for biosimilars in Algeria and the company’s role in developing a local…